Key Takeaways
- Compound: Retatrutide (6.0-day half-life, GLP-1/GIP/glucagon triple agonist)
- Protocol length: 12 weeks covering 2 dosing phases
- Steady state: Reached in approximately 4 weeks at each dose level (estimated from the ~6-day half-life)
- Transition period: In the model, levels approach the new steady state over approximately 4 weeks after a dose change
Investigational Drug: Retatrutide is not FDA-approved and is currently in Phase 3 clinical trials. Lilly is reported to plan an FDA filing in early 2027 (HCPLive, AJMC); FDA's usual review times would put a decision in late 2027 or 2028 (our estimate, not Lilly's). This is an illustrative schedule, not a trial protocol.
Retatrutide Dose Change: What Happens Going from 4mg to 8mg
Quick Answer
Retatrutide has a half-life of 6.0 days. This scenario shows what happens to your blood levels during a dose change. After adjusting the dose, levels begin shifting immediately but take approximately 4 weeks to fully stabilize at the new steady state.
Data computed with the same model and parameters as the GLP3Planner calculators: each dose is absorbed over a day or two and then removed at the rate its published half-life sets. The PK methodology lists every parameter and its source.
Understanding Dose Transitions
When you change your Retatrutide dose, your blood levels do not jump instantly to the new steady state. The transition is gradual because the drug has a 6.0-day half-life, meaning it takes several weeks for the old dose to fully wash out and the new dose to accumulate.
After increasing your dose, each injection adds more drug than before while your body is still eliminating at the old rate. Over approximately 4 weeks, levels climb to the new steady state.
The data below shows the modeled levels during this transition. All values use the same model and parameters as the calculators (see the PK methodology).
Dosing Protocol
| Phase | Weeks | Dose | Frequency | Peak (mg) | Trough (mg) | Syringe Units |
|---|---|---|---|---|---|---|
| Starting dose (5 weekly doses) | 1-5 | 4mg | 1x/week | 5.15 | 2.55 | 40 units |
| New dose | 6-12 | 8mg | 1x/week | 10.47 | 5.29 | 80 units |
Peak and trough are the highest and lowest modelled amounts in the last week of each phase, from the same model and parameters as the calculators (6.0-day published half-life). See methodology.
A phase marked "5 weekly doses" starts from zero, so in the model it ends a few percent short of steady state. A later phase at the same dose can therefore show a slightly higher peak.
What the Numbers Mean
The table above shows modeled drug levels at each phase of this protocol. Here is what each column tells you:
Peak (mg)
The highest modelled amount of Retatrutide in your body in the last week of that phase, reached a day or two after an injection once the dose has been absorbed. In a phase with no injection it is the level at the start of the week.
Trough (mg)
The lowest modelled amount in the last week of that phase, reached just before an injection. This is the minimum drug level in the model between doses.
Steady State (~4 weeks)
The point where drug accumulation stabilizes. Before steady state, each dose adds more drug than your body eliminates, so levels keep climbing. Once reached, the amount in equals the amount out, and your peaks and troughs become consistent from week to week.
These are population-average estimates from the model's parameters, each listed with its source in the methodology. For retatrutide the 80% bioavailability is borrowed from tirzepatide (no figure has been published), and the 1-day time to peak is a median from Phase 1 trials (in the Phase 1b study, blood was sampled mostly 12, 24, 48 and 72 hours after a dose), so treat the figures as approximate. Individual levels vary based on body composition, metabolism, and injection site. For a personalized view, enter your actual doses into the Retatrutide calculator.
Pharmacokinetic Summary
Half-Life
6.0 days
Time for 50% of the drug to be eliminated
Steady State
~4 weeks
Time to reach stable peak/trough levels at each dose
Final Peak Level
10.47 mg
Peak drug amount in the last phase (New dose)
Model Your Own Schedule
Enter your actual doses and timing to see a personalized PK curve with your real data.
Open Retatrutide CalculatorReconstitution Reference
Based on a 20mg vial with 2mL BAC water (10mg/mL):
| Dose | Syringe Units (U-100) | Volume (mL) |
|---|---|---|
| 4mg | 40 units | 0.4mL |
| 8mg | 80 units | 0.8mL |
Units are the marks on a U-100 insulin syringe (1 unit = 0.01mL), not international units.
Need a different concentration? Use our reconstitution calculator. For step-by-step instructions, see the Retatrutide reconstitution guide.
Practical Tips for This Protocol
During the Transition
After a change, the modelled level does not jump straight to its new steady state; it moves toward it over several weeks.
- Weeks 1-2 after the change: the modelled level is still moving toward the new steady state.
- Weeks 3-5 after the change: the level approaches the new steady state, which takes approximately 4 weeks in the model.
- After a missed dose: Retatrutide is investigational and has no FDA-approved label, so there is no label rule for a missed or late dose, and this page does not invent one. Ask whoever supervises your use. In the model, with a 6-day half-life, one missed dose lowers the level but does not clear the drug; the missed dose calculator models the drop for your own dose.
Common Side Effects
In Phase 2 trials, the most common side effects of retatrutide were gastrointestinal: nausea (35-60% depending on dose), diarrhea (20-40%), and constipation (20-30%). These effects were most pronounced during the first 1-2 weeks at each new dose level and typically improved with continued use.[1]
Nausea
Most common during the first few days after an injection or dose increase. Smaller meals, bland foods, and staying hydrated can help. Some people find evening injections reduce daytime nausea.
Digestive Changes
Diarrhea or constipation may occur as the drug slows gastric emptying. Adequate fiber, water, and gentle activity help regulate digestion. These effects typically improve within the first 2-3 weeks at each dose.
Reduced Appetite
This is an expected effect, not a side effect. Make sure you are still eating enough protein and nutrients even when appetite is suppressed. Skipping meals entirely can lead to fatigue and muscle loss.
For a comprehensive list including less common effects, see the full Retatrutide side effects guide.
See Your Own Levels
Enter your actual doses and schedule to get a personalized PK curve.
How This Data Was Computed
Levels come from the same pharmacokinetic model as the GLP3Planner calculators, with the same parameters: each dose is absorbed from under the skin over a day or two, only the bioavailable share reaches the body, and the body removes it at the rate the 6.0-day published half-life sets. Doses are added together (superposition) in 1-hour steps to show how weekly doses accumulate. The figures are modelled amounts in milligrams, not blood test results. For retatrutide the 80% bioavailability is borrowed from tirzepatide (no figure has been published), and the 1-day time to peak is a median from Phase 1 trials (in the Phase 1b study, blood was sampled mostly 12, 24, 48 and 72 hours after a dose), so treat the figures as approximate. Read the full methodology, including data sources and model limitations.
Frequently Asked Questions
How long does Retatrutide stay in your system?
Retatrutide has a half-life of about 6 days. After your last dose the level keeps rising for a day or so while that dose is absorbed, then falls with the 6-day half-life. In the model, after weekly doses the level is below 3% of that peak (about 97% gone) by day 32 after the last dose. By half-life arithmetic, five half-lives (30 days) would leave 3.125%; absorption adds about a day in the model. Some drug remains after that. Use the Retatrutide washout calculator to see the modelled dates for your own dose and last injection.
What is steady state for Retatrutide?
Steady state is when drug accumulation stabilizes, meaning the amount entering your system each dose roughly equals the amount eliminated between doses. For Retatrutide, this takes approximately 4 weeks of consistent dosing at the same level (estimated from the ~6-day half-life). Once at steady state, your peak and trough levels become predictable from week to week.
What happens if I miss a dose of Retatrutide?
Retatrutide is investigational and has no FDA-approved label, so there is no label rule for a missed or late dose, and this page does not invent one. Ask whoever supervises your use. With a 6-day half-life, one missed week lowers your level but does not clear the drug. The Retatrutide missed dose calculator models the drop and the recovery for your own dose and the week you missed; that is a model, not a label instruction.
How accurate is the pharmacokinetic data on this page?
The data uses population-average parameters: the half-life, time to peak and bioavailability listed with their sources in the methodology. For retatrutide the 80% bioavailability is borrowed from tirzepatide (no figure has been published), and the 1-day time to peak is a median from Phase 1 trials (in the Phase 1b study, blood was sampled mostly 12, 24, 48 and 72 hours after a dose), so treat the figures as approximate. Individual drug levels vary based on body composition, metabolism, kidney and liver function, and injection site. The model is most useful for understanding accumulation patterns, steady state timing, and comparing dosing approaches rather than predicting exact personal blood levels. See the full methodology for details.
What is the peak-to-trough ratio and why does it matter?
The peak-to-trough ratio measures how much drug levels fluctuate between injections. For once-weekly Retatrutide at steady state, the model's ratio is about 2.0:1: the peak is about 2.0 times the trough. Higher ratios mean bigger swings between injections. Split dosing reduces this ratio in the model by producing smaller, more frequent peaks.
Is retatrutide FDA-approved?
No. As of 2026, retatrutide is an investigational drug in Phase 3 clinical trials (the TRIUMPH program). Lilly is reported to plan an FDA filing in early 2027 (HCPLive, AJMC); FDA's usual review times would put a decision in late 2027 or 2028 (our estimate, not Lilly's). The schedule on this page is illustrative, not a trial protocol; the half-life comes from Phase 1 studies (Lancet, 2022; Cell Metabolism, 2022),[6][8] the time to peak also comes from Phase 1 data, and the bioavailability is the model's assumption. Check ClinicalTrials.gov for the latest trial status.
Can I use this data to plan my own dosing schedule?
This data is for informational and educational purposes. It shows modeled drug levels for a specific protocol, which can help you understand what to expect and have informed conversations with your doctor. For a schedule tailored to your exact doses, use the interactive Retatrutide calculator.
References
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-hormone-receptor agonist retatrutide for obesity: a Phase 2 trial. N Engl J Med. 2023;389(6):514-526. PubMed
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. PubMed
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(4):327-340. PubMed
- Novo Nordisk. Ozempic (semaglutide) prescribing information. U.S. Food and Drug Administration. FDA Label
- Eli Lilly and Company. Mounjaro (tirzepatide) prescribing information. U.S. Food and Drug Administration. FDA Label
- Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b trial. Lancet. 2022;400(10366):1869-1881. PubMed
- StatPearls. Pharmacokinetics, Steady State. National Center for Biotechnology Information. NCBI Bookshelf
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. PubMed
- Novo Nordisk. Wegovy (semaglutide) prescribing information, sections 2.2 and 2.4. DailyMed. DailyMed
- Eli Lilly and Company. Zepbound (tirzepatide) prescribing information, sections 2.1 and 2.3. DailyMed. DailyMed
Medical Disclaimer
This page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or recommendations. The pharmacokinetic data shown is modeled from population-average clinical trial parameters and does not predict individual drug levels. Always consult your doctor before starting, adjusting, or stopping any medication.
Related Articles
Retatrutide Dosing Guide
Complete titration schedule with clinical trial data and side effects management.
Microdosing Retatrutide
Split-dose protocols, PK comparisons, and practical techniques.
Retatrutide Reconstitution Guide
Step-by-step reconstitution instructions with calculator.
Retatrutide Side Effects
Common and serious side effects with management strategies.
Retatrutide Hub
Everything about Retatrutide in one place: mechanism, trials, dosing, calculators.
PK Methodology
How GLP3Planner calculates drug levels, with clinical data sources.